Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population

BACKGROUND: Quantify association between the glucagon-like peptide-1 receptor agonist liraglutide and risk of thyroid cancer (TC) compared to other antidiabetics. PATIENTS AND METHODS: Initiators of liraglutide, exenatide, metformin, pioglitazone or groups of dipeptidyl peptidase-4 inhibitors or sul...

Descripción completa

Detalles Bibliográficos
Autores principales: Funch, Donnie, Mortimer, Kathleen, Ziyadeh, Najat J, D Seeger, John, Zhou, Li, Ng, Eva, Ross, Douglas, Major-Pedersen, Atheline, Bosch-Traberg, Heidrun, Gydesen, Helge, Dore, David D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203194/
https://www.ncbi.nlm.nih.gov/pubmed/34140791
http://dx.doi.org/10.2147/DMSO.S305496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203194/
https://www.ncbi.nlm.nih.gov/pubmed/34140791
http://dx.doi.org/10.2147/DMSO.S305496

Ejemplares similares